CJC-1295 and ipamorelin are the peptide world's famous pairing, named together so often people assume they're two halves of one thing. Here's what actually distinguishes them.

Two complementary mechanisms

CJC-1295 is a long-acting GHRH analog, in the same broad family as sermorelin, studied for its influence on growth-hormone and IGF-1 signaling. Ipamorelin is a growth-hormone secretagogue acting through the ghrelin pathway. Because they engage different mechanisms, they're frequently discussed in combination, which is exactly why you see them paired.

The status

Neither CJC-1295 nor ipamorelin is FDA-approved, and both sit within the broader, shifting 2026 conversation about peptide compounding. "Discussed together" in forums is not the same as "proven or approved."

They're paired so often it feels official. The pairing is a community convention, not an approved protocol.
No protocol here

We don't publish doses, schedules, or administration instructions. These compounds aren't FDA-approved, and turning early research into a self-use guide would misrepresent the evidence and the risk. Whether anything is appropriate is a decision for a licensed provider.

Bottom line

Different mechanisms, often discussed as a pair, neither approved. See our CJC-1295 and Ipamorelin guides, and bring the pairing question to a licensed provider.